Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2021 16:02 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates

Continued Strong Enrollment in TRIDENT-1 Registrational Study, with Phase 1/2 Enrollment in EXP-1 Expected to Reach 50 Patients in 2Q; Type B Meeting with FDA Planned in 2QTPX-0131 Phase 1/2 Study...
February 18, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
February 04, 2021 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
January 29, 2021 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Phase 2 Confirmed Objective Response Rate is 93% (95% CI: 68-100); Pooled Phase 1/2 Confirmed Objective Response Rate is 91% (95% CI: 71-99)Approximately 40 Patients with ROS1-Positive TKI-Naive...
January 11, 2021 07:40 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces 2021 Milestone Targets

Present Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Jan. 31 at World Conference on Lung CancerProvide TRIDENT-1 Study Timeline in First...
January 11, 2021 04:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point and Zai Lab Broaden Collaboration

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to...
December 08, 2020 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
November 12, 2020 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022, Recently Presented Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update...
November 10, 2020 16:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
October 29, 2020 16:15 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...